» Articles » PMID: 29552145

Novel TLR7 Agonist Stimulates Activity of CIK/NK Immunological Effector Cells to Enhance Antitumor Cytotoxicity

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Mar 20
PMID 29552145
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine [termed Gao Dong (GD)], a novel TLR7 agonist, in the activation of cytokine-induced killer/natural killer (CIK/NK) cells was determined. The results of the present study indicated that GD was able to activate CIK/NK cells. The proportion of GD-induced CD3CD56 CIK and CD3CD56 NK cells was ~4% higher respectively compared with the control. Notably, combination therapy with CIK/NK cells stimulated by GD, markedly suppressed the proliferation of the chronic myelogenous leukemia K562 cell line. Following GD treatment, the cytotoxicity improved by ~25 and 21% when the effector/target ratio was 20:1 and 10:1, respectively. The results of the present study suggested a novel protocol for CIK/NK cell proliferation and revealed that GD may serve as a potent innate and adaptive immunomodulator in immunocyte culture.

Citing Articles

Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells.

Zhang C, Xiong X, Li Y, Huang K, Liu L, Peng X Oncol Lett. 2019; 18(6):6525-6535.

PMID: 31807172 PMC: 6876305. DOI: 10.3892/ol.2019.11020.

References
1.
Pittari G, Filippini P, Gentilcore G, Grivel J, Rutella S . Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol. 2015; 6:230. PMC: 4429635. DOI: 10.3389/fimmu.2015.00230. View

2.
Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N . A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2013; 34(2):194-203. DOI: 10.1007/s10875-013-9976-0. View

3.
Lee M, Park C, Lee Y, Im S, Song S, Lee C . Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014; 37(9):1234-40. DOI: 10.1007/s12272-014-0379-4. View

4.
Abrahamsen I, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord G . Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005; 90(1):86-93. View

5.
Alvarnas J, Linn Y, Hope E, Negrin R . Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):216-22. DOI: 10.1053/bbmt.2001.v7.pm11349808. View